📊 BLFS Key Takeaways
Investment Thesis
BioLife Solutions demonstrates strong revenue growth of 28.9% YoY with excellent gross margins of 64.6%, indicating pricing power and operational efficiency in its core products. However, the company remains unprofitable with negative operating margins of -17.3% and operating losses of $16.6M, suggesting R&D or commercialization expenses are outpacing revenue growth, though improving net losses YoY provide some encouragement.
BLFS Strengths
- Strong revenue growth of 28.9% YoY indicates healthy market demand and successful commercial execution
- Excellent gross margin of 64.6% demonstrates strong pricing power and cost management of core products
- Fortress balance sheet with minimal debt (0.01x leverage), $33M cash, and exceptional liquidity ratios (5.94x current, 4.63x quick)
- Positive free cash flow of $10.6M (11.1% FCF margin) despite net losses shows underlying business generating cash
- Net loss improvement of 77.2% YoY and EPS improvement of 77.3% suggests trajectory toward profitability
BLFS Risks
- Significant operating loss of $16.6M with -17.3% operating margin indicates company is not yet at scale profitability
- Operating cash flow of $20.1M only marginally exceeds capex of $9.5M, leaving limited buffer for growth investments
- Negative ROE and ROA metrics indicate shareholder capital is not yet being deployed productively to generate returns
- Heavy insider trading activity (25 Form 4 filings in 90 days) warrants monitoring for potential capital allocation concerns
- Sector is highly competitive and capital-intensive; sustained ability to convert gross margin to operating income not yet proven
Key Metrics to Watch
- Operating margin trajectory toward positive territory and path to EBITDA profitability
- Operating expense growth rate relative to revenue growth to demonstrate operating leverage
- Free cash flow sustainability and capex as percentage of revenue to assess reinvestment efficiency
- Gross margin stability to ensure pricing power and product mix remain favorable
BLFS Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.94x current ratio provides a solid financial cushion.
BLFS Profitability Ratios
BLFS vs Healthcare Sector
How BIOLIFE SOLUTIONS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BLFS Balance Sheet & Liquidity
BLFS 5-Year Financial Trend
5-Year Trend Summary: BIOLIFE SOLUTIONS INC's revenue has declined by 19% over the 5-year period, indicating business contraction. The most recent EPS of $-1.55 indicates the company is currently unprofitable.
BLFS Growth Metrics (YoY)
BLFS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $21.4M | $621.0K | $0.01 |
| Q2 2025 | $19.7M | -$15.8M | $-0.33 |
| Q1 2025 | $18.4M | -$448.0K | $-0.01 |
| Q3 2024 | $23.6M | -$1.7M | $-0.04 |
| Q2 2024 | $28.3M | -$10.2M | $-0.23 |
| Q1 2024 | $31.7M | -$10.2M | $-0.22 |
| Q3 2023 | $33.3M | -$10.3M | $-0.24 |
| Q2 2023 | $39.5M | -$10.2M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BLFS Capital Allocation
BLFS SEC Filings
Access official SEC EDGAR filings for BIOLIFE SOLUTIONS INC (CIK: 0000834365)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 9, 2026 | 4 | xslF345X05/wk-form4_1773094257.xml | View → |
| Mar 5, 2026 | 4 | xslF345X05/wk-form4_1772748632.xml | View → |
| Mar 5, 2026 | 4 | xslF345X05/wk-form4_1772748626.xml | View → |
| Mar 5, 2026 | 4 | xslF345X05/wk-form4_1772748620.xml | View → |
| Mar 5, 2026 | 4 | xslF345X05/wk-form4_1772748614.xml | View → |
❓ Frequently Asked Questions about BLFS
What is the AI rating for BLFS?
BIOLIFE SOLUTIONS INC (BLFS) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BLFS's key strengths?
Strong revenue growth of 28.9% YoY indicates healthy market demand and successful commercial execution. Excellent gross margin of 64.6% demonstrates strong pricing power and cost management of core products.
What are the risks of investing in BLFS?
Significant operating loss of $16.6M with -17.3% operating margin indicates company is not yet at scale profitability. Operating cash flow of $20.1M only marginally exceeds capex of $9.5M, leaving limited buffer for growth investments.
What is BLFS's revenue and growth?
BIOLIFE SOLUTIONS INC reported revenue of $96.2M.
Does BLFS pay dividends?
BIOLIFE SOLUTIONS INC does not currently pay dividends.
Where can I find BLFS SEC filings?
Official SEC filings for BIOLIFE SOLUTIONS INC (CIK: 0000834365) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BLFS's EPS?
BIOLIFE SOLUTIONS INC has a diluted EPS of $-0.10.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.